Arbutus Biopharma finalizes separation agreements with ex-CMO and ex-CFO; updates Moderna trial date

Arbutus Biopharma Corp

CMO Karen Sims terminated without cause effective March 25, 2025; enters 30-day consulting agreement with hourly fee and extended option exercise to March 24, 2026.
CFO David Hastings terminated without cause effective March 27, 2025; separation agreement extends option exercise to March 26, 2026.
Patent litigation vs Moderna: District of Delaware moved trial start from September 24 to September 29, 2025.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Karen Sims

Chief Medical Officer

ABUS · Arbutus Biopharma Corp

Effective: 2025-03-25
Filed: April 3, 2025, 7:59 PM ET

the Company terminated, without cause, Karen Sims, M.D., Ph.D. as Chief Medical Officer of the Company, effective March 25, 2025.

Departed

David Hastings

Chief Financial Officer

ABUS · Arbutus Biopharma Corp

Effective: 2025-03-27
Filed: April 3, 2025, 7:59 PM ET

the Company terminated, without cause, David Hastings as Chief Financial Officer of the Company, effective as of the end of the day on March 27, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen Sims departed as Chief Medical Officer at Arbutus Biopharma Corp.

Action: terminated without cause
Role: Chief Medical Officer

Exact text from the filing

the Company terminated, without cause, Karen Sims, M.D., Ph.D. as Chief Medical Officer of the Company, effective March 25, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Hastings departed as Chief Financial Officer at Arbutus Biopharma Corp.

Action: terminated without cause
Role: Chief Financial Officer

Exact text from the filing

the Company terminated, without cause, David Hastings as Chief Financial Officer of the Company, effective as of the end of the day on March 27, 2025.

View on SEC.gov

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001447028-25-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.